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Abstract
Background: Benign prostatic hyperplasia (BPH) is the most common canine prostatic disorder. Although most or
even all intact male dogs may develop BPH by 5–8 years of age, many show no clinical signs. Taking into account
the non-specific character of clinical and ultrasonographic findings, a new diagnostic approach has recently been
proposed based on the augmentation of blood canine prostate-specific arginine esterase (CPSE) in hyperplasic
dogs. The aim of the present study was to verify CPSE levels in negative controls and hyperplasic dogs, considering
cytological findings as the reference method and taking into account the fact that controls were middle-aged
intact dogs (median of 5.0 years), contrarily to previous studies carried out with very young control dogs.
Results: Significant differences of median CPSE levels were found between controls and hyperplasic dogs (29.1
versus 160.7 ng/mL, respectively); and significant positive correlations were found between median CPSE levels and
age or prostatic volume (r = 0.549 and 0.448, respectively; p < 0.001). Sensitivity, specificity, positive and negative
likelihood ratios put into evidence the good performance of the test. The agreement between methods was found
to be very high, notably between CPSE levels and cytological results (Cohen’s kappa coefficients above 0.8).
Conclusions: Considering the results all together, measurement of CPSE is confirmed as a useful and accurate
method and should be considered as an alternative or complementary tool to conventional methods for the
diagnosis of BPH in middle-aged dogs.
Keywords: Prostate, Benign prostate hyperplasia, BPH, Canine prostate-specific arginine esterase, CPSE, Biomarker
Background
Diseases of the prostate are common in middle-aged to
older intact dogs. The canine prostate can be affected by
benign prostatic hyperplasia (BPH), squamous metapla-
sia, cysts, inflammation and neoplasia. BPH, the most
common prostatic disorder, is a spontaneous disease of
intact male dogs that begins as glandular hyperplasia as
early as 2 years of age [1]. Dihydrotestosterone is
accepted as a key hormone in the pathogenesis of the
disease, stimulating enlargement of the prostate by
enhancing growth of both the stromal and glandular
components [2]. Oestrogens, in particular the ratio of
17β-oestradiol/testosterone, are also involved in the
development of BPH, as is potentially prolactin [3] and
also other mitogenic growth factors [4, 5].
When present, clinical signs of BPH include serosan-
guinous urethral discharge not associated with urination
[6], hemospermia and hematuria, tenesmus, poor semen
quality and infertility, and prostatomegaly [7], as well as
constipation and dysuria [3]. The diagnosis of BPH is
usually based on history, physical and/or andrologic
exam and abdominal ultrasonography; and seldom on
cytology by fine needle-aspiration (FNA). Palpation usu-
ally reveals a symmetrically enlarged and non-painful
prostate. The presence of prostatomegaly confirmed by
ultrasonography (with a heterogeneous or hyperechoic
parenchyma with or without fluid-filled cysts) is frequently
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sufficient to reach a conclusive diagnosis of BPH [7].
However, BPH can be difficult to differentiate from other
prostatic diseases, including squamous metaplasia, prosta-
titis, prostatic cysts and abscesses, and prostatic neoplasia,
due to the similarity of clinical and ultrasonographic find-
ings. Under these circumstances, other methods should be
used, i.e., cytology or biopsy, and more recently the seric
quantification of canine prostate-specific arginine esterase
(CPSE) [8].
CPSE, a serine protease similar to the human prostate-
specific antigen (“PSA”), is the most important specific
androgen-dependent protein of prostatic secretion in
dog and a remarkable marker of androgenic stimulation
[9, 10]. Serum CPSE concentrations, as determined by
immunoprecipitation, were found to be significantly ele-
vated in dogs with BPH compared to normal dogs [11].
CPSE determination by enzyme-linked immunosorbent
assay (ELISA) is currently an interesting method for
BPH diagnosis, especially indicated to early detect dogs
with a subclinical pathological condition, and opens new
perspectives to the follow-up of medical treatment [8].
However, there is scarce information on CPSE levels in
middle-aged healthy dogs. In such animals, the deter-
mination of CPSE concentration is a feasible procedure
that can be of high importance for early BPH diagnosis.
The aims of the present study were: a) to compare
CPSE levels in dogs with BPH (study group) and without
BPH (control group); and b) to compare clinical, ultra-
sonographic and CPSE performances in the diagnosis of
BPH, considering the cytological marks as the reference
method for this study.
Methods
Clinical, ultrasonographic and cytological evaluations
All the dogs (n = 60) were evaluated only after an
informed consent obtained from their owners. Each dog
underwent clinical examination including a thorough
history, physical and digital rectal examination (DRE) of
the prostate, ultrasonography and cytological evaluation.
Clinical manifestations compatible with BPH or cystic
prostatic hyperplasia (CPH) comprised constipation,
ribbon-like stools, hemorrhagic urethral discharge and/
or intermittent hematuria, weight loss, rear limbs pain
and abnormal DRE, such as palpable prostatomegaly and
painful or abnormal prostate such as nodularity, indura-
tions or asymmetry [12]. Prostatitis was suspected when
clinical signs were more severe than BPH, as caudal
abdominal or pelvic pain, and a diffuse to asymmet-
rical enlargement and/or prostatic pain was noted at
DRE [13].
Additional procedures carried out comprised prostatic
ultrasonography, prostatic massage or prostatic FNA for
cytological evaluation (Figs. 1 and 2). Transabdominal
ultrasonography of the prostate was performed with a
Philips HD3 Ultrasound system (Philips Healthcare,
USA), using a sectorial 3.0-7.0 MHz and linear 5.0-
9.0 MHz transducers. The ultrasonographic examination
enabled the evaluation of the prostate size, namely
length (L) and height in the longitudinal plan (HL), and
height (HT) and width (W) in the transverse one, plus
shape, position, internal echogenicity and margins. The
values for L, HL/HT and W were the average of three
consecutive measurements. Prostatic volume (PV) was
determined by the formula PV (cm3) = 0.487 × L ×W ×
(HL ×HT/2) + 6.38; and the expected volume (EV) was
determined by the formula EV (cm3) = 8.48 + [0.238 ×
body weight (kg)] [14]. All variations of the normal
ultrasonographic aspect were recorded (i.e., asymmetric
Fig. 1 Fine needle-aspirate from a prostate with benign hyperplasia
(group A dog). Cells are arranged in clusters and show a uniform
morphology with round nucleus and basophilic cytoplasm (Diff-quick
staining; bar = 500 μm)
Fig. 2 Fine needle-aspirate from a normal prostate (group C dog).
Cells are arranged in small clusters with a uniform morphology,
showing round nucleus and clear cytoplasm (Diff-quick staining;
×600 magnification)
Pinheiro et al. BMC Veterinary Research  (2017) 13:76 Page 2 of 7
shape, size, and aspect of focal or multifocal variations
of echogenicity; size and echogenicity of retention cysts
or areas of cavitation; and irregular margins). Abnormal
records of ultrasonography included BPH-suggestive, cys-
tic prostatic hyperplasia (CPH)-suggestive and prostatitis-
suggestive ultrasonograms. Ultrasonographic findings
were subdivided into simple BPH, CPH and prostatitis.
Findings compatible with BPH included symmetrical pros-
tatic enlargement and diffusely hyperechoic parenchyma,
whereas CPH showed hyperechoic parenchyma back-
ground with cavitary lesions of varying architecture and
distal acoustic enhancement. Prostatitis was suspected
when ultrasonographic findings were more pronounced
than BPH, being the prostate variably hyperechoic with a
more complex contour [13].
For cytology, samples were collected by ultrasound-
guided transabdominal FNA, as previously described [6]
or by prostatic massage, namely when ultrasonography
suggested prostatitis [15]. The cells were then smeared on
a slide, air-dried, stained with Diff-Quick and mounted
with EntellanTM (Merck Millipore, USA). The presence of
uniform sheets or clusters of prostatic cells with middle
anysokaryosis and increased size with round and small
nucleus, with a basophilic, moderate cytoplasm are the
cytological criteria to determine the presence of BPH [16].
These clusters could be in a high quantity but their cells
appeared as normal epithelial prostatic ones. The cytology
of prostatitis is determined by the presence of a large
number of neutrophils associated with a variable numbers
of macrophages (more common in chronic prostatitis).
Bacteria could be present, both freely or intracytoplasma-
tically (i.e., inside neutrophils and macrophages). Finally,
squamous metaplasia is determined by the presence of
prostatic cells with squamous epithelial characteristics
such as large and clear to basophilic cytoplasm with small
dense nucleus [16].
Groups of animals
Based on cytological results, two groups of adult
intact male dogs were formed, i.e., a study group (A;
Table 1; Additional file 1) and a control group (C;
Table 2; Additional file 2).
Group A included eight mongrels and 21 other dogs
from 13 defined breeds, i.e., Labrador Retriever (n = 4),
Boxer (n = 3), Estrela Mountain Dog (n = 3), Golden Re-
triever (n = 2), Beagle (n = 1), Brittany (n = 1), Chow-
Chow (n = 1), Cocker Spaniel (n = 1), Dalmatian (n = 1),
Pekingese (n = 1), Portuguese Sheepdog (n = 1), Rott-
weiler (n = 1) and Siberian Husky (n = 1). Weight ranged
from 8 to 59 kg, with a median of 30.0 kg (interquartile
range [IQR]: 23.0-35.2). Age ranged from 5 to 15 years,
with a median of 9.0 years (IQR: 7–11.5).
Group C included eight mongrels and 23 other dogs
from 15 defined breeds, i.e., Beagle (n = 5), Brittany (n =
2), German Shepherd (n = 2), Golden Retriever (n = 2),
Cocker Spaniel (n = 1), Drever (n = 1), Estrela Mountain
Dog (n = 1), French Bulldog (n = 1), German Spitz Klein
(n = 1), German Spitz Mittel (n = 1), Labrador Retriever
(n = 1), Miniature Pinscher (n = 1), Portuguese Pointer
(n = 1), Portuguese Water Dog (n = 1), St. Bernard (n =
1) and Transmontano Mastiff (n = 1). Weight ranged
from 4 to 70 kg, with a median of 19.0 kg (IQR: 13.0-
33.0). Age ranged from 1 to 12 years, with a median of
5.0 years (IQR: 2.0-7.0).
Canine prostate-specific arginine esterase (CPSE)
Blood was collected from all the dogs, left to clot for 4 h
at room temperature and the collected serum kept fro-
zen at −25 °C until use. In order to measure plasma
CPSE concentrations, an enzyme-linked immunosorbent
assay (ELISA) was used strictly following the manufac-
turer’s instructions (Odelis® CPSE, Virbac, France).
Briefly, dilutions of the ELISA stock solution were done
to obtain the different calibrator solutions (20, 10, 5.0,
2.5 and 0.0 ng/ml) and to define the standard curve. All
the plasma samples were diluted at 1:10 and incubated
at 37 °C for 1 h before being assayed. The horseradish
peroxidase conjugate were placed into each well after
washing cycle and incubated again at 37 °C for 1 h. After
another washing cycle, tetramethylbenzidine was added
for 10 min and the reaction then stopped. The optical
density (“OD”) of each sample was read at 450 nm and
CPSE plasma concentrations calculated based on the
standard curve plotted with calibrator concentrations. A
CPSE value of 61 ng/ml was set as the cut-off for
BPH (i.e., values equal to or greater that the cut-off
were regarded as positive), according to the manufac-
turer’s instructions.
Table 1 Records from clinical examination, ultrasonography and
cytology in 29 dogs (group A) diagnosed with benign prostatic








Physical signs DRE BPH CPH Prostatitis
Absent Normal No No Yes 1
Abnormal No Yes No 2
Yes 1
Yes No No 3
Present Normal No Yes No 3
Yes 2
Yes No No 1
Abnormal Yes No No 5
No Yes No 7
Yes 4
CPH cystic prostatic hyperplasia, DRE digital rectal examination
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Data analysis
The agreement beyond chance between binomial results
(i.e., positive or negative) of CPSE and those of the clin-
ical, ultrasonographic and cytological evaluations for
BPH was measured with Cohen’s kappa coefficient (k).
Sensitivity (true positive [TP]/TP + false negative), speci-
ficity (true negative [TN]/TN + false positive), positive
likelihood ratio (sensitivity/1 – specificity) and negative
likelihood ratio (1 – sensitivity/specificity) were calcu-
lated for CPSE binomial results taking cytology as the
reference method. Exact binomial 95% confidence inter-
vals (CI) were established for proportions. Differences in
the CPSE levels between groups A and C were assessed
by means of the Mann-Whitney U test. The association
between CPSE levels and other quantitative variables
(i.e., age, PV and EV) was measured by Spearman’s rank
correlation coefficient r [17]. Analyses were performed
with SPSS 21.0 software for Windows, with a p value <
0.05 as statistically significant.
Results
CPSE levels between groups
The levels of CPSE (Fig. 3) were significantly different
(p < 0.001) between group A (median: 160.7 ng/ml; IQR:
80.8–220.5) and group C (median: 29.1 ng/ml; IQR:
19.3–45.5). Significant (p < 0.001) correlations were
found between age and CPSE level (r = 0.549) and CPSE
and PV (r = 0.448); but not between CPSE and EV (r =
0.193; p = 0.139).
Clinical, ultrasonographic and cytological records
In Group A (study group), all 29 dogs evidenced BPH
confirmed by cytology; moreover, eight (of these) dogs
showed prostatitis concomitant with BPH (proved by the
presence of a large number of neutrophils and associated
macrophages, and variable amounts of uniform clusters
of prostatic cells with middle anysokaryosis and in-
creased size, round and small nucleus, with a clear or
moderately basophilic cytoplasm, a characteristic of
prostatitis with BPH). In Group C (control group; 31
dogs without BPH proved by cytology), six dogs had
prostatitis and two other had squamous metaplasia
(presence of large epithelial prostatic cells with a clear to
basophilic cytoplasm, and a small dense nucleus similar
to that of keratinocytes).
Comparison between CPSE levels, clinical,
ultrasonographic and cytological evaluations
The k values from comparisons between binomial CPSE
levels and clinic evaluation, ultrasonography and cy-
tology were 0.83, 0.83 and 0.87, respectively (Table 3). A
k value above 0.80 represents an almost perfect agree-
ment beyond chance.
Three out of the 31 dogs of group C had a positive
CPSE result. Two of those three dogs had prostatitis and
CPSE values of 174.0 and 183.0 ng/ml; the other animal
Table 2 Records from clinical examination, ultrasonography and cytology in 31 dogs (group C) without benign prostatic hyperplasia
(BPH) as determined by cytological examination of prostatic aspirates
Clinical examination Ultrasonography-suggested
condition
Cytology (BPH−) Dogs (n)
Physical signs DRE BPH CPH Prostatitis Prostatitis Metaplasia
Absent Normal No No No No No 23
Yes No 2
Abnormal No Yes No Yes No 1
Present Normal No No No No No 1
Yes Yes No 1
Abnormal No Yes No No Yes 1
Yes Yes 1
Yes No No Yes No 1
CPH cystic prostatic hyperplasia, DRE digital rectal examination
Fig. 3 Canine prostate-specific arginine esterase (CPSE) levels in 29
dogs (group A) with benign prostatic hyperplasia (BPH), as diagnosed
by cytology; and in 31 dogs (group C) without BPH (p < 0.001). The
dotted line represents the cut-off value for CPSE (i.e., values≥ 61 ng/ml
were regarded as a positive result)
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had squamous metaplasia and a CPSE value of 147.0 ng/
ml.
One dog of group A had a CPSE level of 45.2 ng/ml.
Sensitivity of the CPSE binomial results (positive or
negative) was 96.6% (95% CI: 82.2–99.4), specificity
90.3% (95% CI: 74.2–97.9), positive likelihood ratio 10.0
(95% CI: 3.4–29.3) and negative likelihood ratio 0.04
(95% CI: 0.01–0.26). A positive likelihood ratio of 10.0
reveals a moderate to large and often conclusive increase
in the likelihood of BPH if the CPSE result is positive.
On the other side, a negative likelihood ratio of 0.04
stands for a large and often conclusive decrease in the
likelihood of BPH if the CPSE result is negative.
Discussion
Prostatic diseases are frequent age-related conditions in
intact dogs. The importance of applying a systematic
diagnostic protocol that allows an accurate identification
of prostatic disorders should be emphasized, as this pro-
vides the chance of an early control of the disorder with-
out development of chronic disease, which is hard to
manage and causes deterioration of fertility [18].
Several diagnostic methods can be used to evaluate
the prostate, from physical examination (i.e., DRE) to
ultrasonography, assessment of ejaculate’s third fraction,
prostatic massage, prostatic FNA and biopsy [19]. Data
obtained from clinical examination are important as
starting points for further evaluation of the prostate.
Nevertheless, clinical signs of prostatic disease can be
transitory and unspecific, precluding a desirably early
and conclusive diagnosis. Assessment of the ejaculate’s
third fraction could have been an adequate criterion to
evaluate prostatic disease. However, taking into account
that males included in the study were not breed dogs,
semen collection was not attempted. Prostatic ultrason-
ography is an excellent method in the evaluation of the
position, size, contours, and parenchymal echogenicity,
as well as in the evaluation of the prostatic urethra.
Jointly, clinical evaluation of the prostate and ultrason-
ography could allow a presumptive diagnosis of the
prostatic condition in a reasonable number of cases, but
sensitivity would not be optimal (i.e., the ability of
detecting all the positive cases). Other methods should
then be carried out, such as the prostatic massage and/or
the invasive FNA and biopsy [15]. Ultrasound-guided
transabdominal FNA was used in this study as the pre-
ferred method to obtain prostatic tissue and fluid, and
then as the gold standard to which the other methods
were compared, considering the very high agreement
between FNA and histopathological diagnosis [20] and
also the availability of this technique. Besides, the thin
monolayer obtained with cytological smears often allows
better assessment of individual cytomorphology, as well as
improved detection of etiologic agents [21]. Prostatic bi-
opsy is only considered in cases where less invasive diag-
nostic tests do not render a conclusive diagnosis [6, 19].
Under the above-mentioned circumstances, when it
comes to obtain an accurate diagnosis prior to initiating
a treatment, several tests can be carried out, taking
always into account the benefits, costs and risks of each
procedure. Also considering the fact that there is still
room for improvement, novel molecular tools have been
proposed to early detect prostatic diseases such as the
CPSE ELISA kit, which allows determination of CPSE
levels in an expeditious manner. In the present study,
CPSE levels were determined after the formation of two
defined groups, i.e., a study and a control, in which ani-
mals were cytologically confirmed as having BPH or not
having-BPH, respectively. CPSE serum values were sig-
nificantly higher in BPH than in non-BPH dogs, which
indicate an increased production and secretion of this
marker by prostatic epithelial cells in animals with BPH,
and further confirm the diagnostic value of the test. Fur-
thermore, seven dogs in group A (BPH positive) had at
least one clinical sign but no changes at DRE, while
seven other showed no clinical signs. Considering that
these dogs were older than 5 years old, the present study
highlights the importance of systematic CPSE quantifica-
tion in middle-aged dogs even when apparently healthy.
An early BPH diagnosis in these dogs is always desirable
considering the impact of the disorder in fertility [22].
CPSE determination is furthermore useful when ultra-
sonography is not available or for diagnosis in large and
obese dogs in which DRE could be impossible, and also
of great utility in the follow-up of BPH medical treat-
ment. CPSE determination does not preclude the attain-
ment of other complementary tests used to exclude the
coexistence of other prostatic diseases, such as prostatitis,
squamous metaplasia or neoplasia, which are especially
recommended when clinical examination and/or ultrason-
ography are suggestive of disorders other than BPH.
CPSE levels were moderately correlated with prostatic
volume (PV), which could be explained by the elevated
secretion of CPSE in enlarged hyperplasic prostates.
There was no correlation between CPSE and the ex-
pected volume (EV) of the prostate, as the latter adjusts
Table 3 Comparison between the binomial results of canine
prostate-specific arginine esterase (CPSE; a value ≥ 61 ng/ml
was regarded as positive) and those of clinical evaluation,
ultrasonography and cytology for the diagnosis of benign
prostatic hyperplasia (BPH) in dogs
CPSEa, b, c Clinical evaluationa Ultrasonographyb Cytologyc
+ve –ve +ve –ve +ve –ve
+ve 30 1 29 2 28 3
–ve 4 25 3 26 1 28
Total 34 26 32 28 29 31
a: k = 0.83; b: k = 0.83; c: k = 0.87; +ve: positive; −ve: negative
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prostate size to the weight of dogs. Another important
finding is the fact that, although there were significant
differences between median weights of the dogs in the
two groups, no statistically significant correlation was
detected between weight and CPSE levels, a fact which
indicates reliability of the test for large breeds.
In group A (study), seven out of 29 dogs with BPH –
i.e., with high CPSE values – also presented prostatitis.
The association of various prostatic disorders is not un-
common; in fact, diseased prostate glands are commonly
affected by multiple and even co-existing pathological
conditions [18]. CPH could predispose prostate to in-
flammation by providing a favorable medium for bacter-
ial growth or by interference with normal defense
mechanisms [4]. The hypothesis that inflammation
emerges as the major contributor for the development
of BPH has been suggested in men [23]. On the other
hand, in group C (control), six out of 31 dogs presented
prostatitis, with two of them showing CPSE increased
values, which could indicate the need of following up
these animals. Previous studies have found no difference
between serum concentrations of CPSE in dogs with
BPH and in those with bacterial prostatitis and carcin-
oma, which was attributed to the existence of concur-
rent BPH [11]. However, the method for CPSE
determination was different from the current one. In the
present study, this could be excluded considering that
cytological analysis ruled out BPH in group C. The
remaining dogs of group C with prostatitis showed low
CPSE values, like the dogs without BPH in the same
group. Further studies with large numbers of dogs
should contribute to clarify these findings.
Conclusions
Results of the present study revealed a very high agree-
ment (i.e., almost perfect) between CPSE test and other
diagnostic tools for BPH diagnosis. Previous studies have
suggested cytological evaluation as one of the methods
with higher accuracy in the diagnosis of prostatic diseases
[20], which was also observed in the present study, with
the highest agreement found between the CPSE test and
cytological diagnosis. The CPSE test can very accurately
differentiate between dogs with and without BPH and
may be considered as an alternative or complementary
tool to conventional methods for BPH diagnosis. Finally,
its systematic use can increase the likelihood of early diag-
nosing BPH in apparently healthy middle-aged dogs.
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